Our onco-metabolism approach brings
an enhanced perspective to cancer.
- Company
- Therapeutic Areas
- Programs
- Clinical Trials
- Media & Investors
- Financial Information
- Corporate Governance
- Shareholder Services
-
INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium
-
Calithera to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
-
Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint
-
Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Development Pipeline
Calithera is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted, small molecule therapies that disrupt cellular metabolic pathways to preferentially block tumor cell growth and enhance immune-cell activity.
Recent News
- Shareholder Services
- Corporate Governance
- Financial Information
- Media & Investors
- Clinical Trials
- Programs
- Therapeutic Areas
